Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4182
Out of 5,218 analysts
13
Total ratings
33.33%
Success rate
-6.08%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ANI Pharmaceuticals | Initiates Coverage On: Outperform | 80 | 56.38 | 41.89% | 1 | Dec 11, 2024 | |
Zura Bio | Initiates Coverage On: Outperform | 15 | 2.29 | 555.02% | 1 | Nov 4, 2024 | |
Trevi Therapeutics | Assumes: Outperform | 7 | 4.17 | 67.87% | 1 | Sep 9, 2024 | |
PureTech Health | Assumes: Outperform | 45 | 20.58 | 118.66% | 1 | Sep 9, 2024 | |
Pliant Therapeutics | Assumes: Outperform | 33 | 13.2 | 150% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 5 | 3.52 | 42.05% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 26.76 | -10.31% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 3.86 | 81.35% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 6.54 | 22.32% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 60 | 41.98 | 42.93% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 1.13 | 342.48% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | n/a | n/a | 1 | Mar 21, 2023 |